Altered intestinal Streptococcus anginosus and 5α-reductase gene levels in patients with hepatocellular carcinoma and elevated Bacteroides stercoris in atezolizumab/bevacizumab non-responders
Journal of Medical Microbiology · 06.09.2024 · 73 (9)
DOI: 10.1099/jmm.0.001878 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Microbiology, erschienen am 06.09.2024. Verfasst von Tadashi Fujii und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Fujita Health University, Aichi, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Gastrointestinal Microbiome, Bacteroides. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science London.
Abstract (Originalsprache)
Introduction
Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide. Gap statement. Monitoring of HCC and predicting its immunotherapy responses are challenging.
Aim
This study explored the potential of the gut microbiome for HCC monitoring and predicting HCC immunotherapy responses.
Methods
DNA samples were collected from the faeces of 22 patients with HCC treated with atezolizumab/bevacizumab (Atz/Bev) and 85 healthy controls. The gut microbiome was analysed using 16S rRNA next-generation sequencing and quantitative PCR (qPCR).
Results
The microbiomes of patients with HCC demonstrated significant enrichment of Lactobacillus , particularly Lactobacillus fermentum , and Streptococcus , notably Streptococcus anginosus . Comparative analysis between Atz/Bev responders (R) and non-responders (NR) revealed a higher abundance of Bacteroides stercoris in the NR group and Bacteroides coprocola in the R group. Using qPCR analysis, we observed elevated levels of S. anginosus and reduced levels of 5α-reductase genes, essential for the synthesis of isoallolithocholic acid, in HCC patients compared to controls. Additionally, the analysis confirmed a significantly lower abundance of B. stercoris in the Atz/Bev R group relative to the NR group.
Conclusions
The gut microbiome analysis and specific gene quantification via qPCR could provide a rapid, less invasive, and cost-effective approach for assessing the increased risk of HCC, monitoring patient status, and predicting immunotherapy responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Fujita Health University, Aichi, Japan.
- Department of Medical Research on Prebiotics and Probiotics, Fujita Health University, Aichi, Japan.
- BIOSIS Lab. Co. Ltd., Aichi, Japan.
- WELLNEO SUGAR Co., Ltd., Tokyo, Japan.
Förderung
- Japan Society for the Promotion of Science London
Zitieren
APA
Fujii, T., Kuzuya, T., Kondo, N., Funasaka, K., Ohno, E., Hirooka, Y., & Tochio, T. (2024). Altered intestinal Streptococcus anginosus and 5α-reductase gene levels in patients with hepatocellular carcinoma and elevated Bacteroides stercoris in atezolizumab/bevacizumab non-responders. Journal of Medical Microbiology, 73(9). https://doi.org/10.1099/jmm.0.001878
Vancouver
Fujii T, Kuzuya T, Kondo N, Funasaka K, Ohno E, Hirooka Y, et al. Altered intestinal Streptococcus anginosus and 5α-reductase gene levels in patients with hepatocellular carcinoma and elevated Bacteroides stercoris in atezolizumab/bevacizumab non-responders. Journal of Medical Microbiology. 2024;73(9). doi:10.1099/jmm.0.001878
BibTeX
@article{Fujii2024,
author = {Fujii, Tadashi and Kuzuya, Teiji and Kondo, Nobuhiro and Funasaka, Kohei and Ohno, Eizaburo and Hirooka, Yoshiki and Tochio, Takumi},
title = {Altered intestinal Streptococcus anginosus and 5α-reductase gene levels in patients with hepatocellular carcinoma and elevated Bacteroides stercoris in atezolizumab/bevacizumab non-responders},
journal = {Journal of Medical Microbiology},
year = {2024},
volume = {73},
number = {9},
doi = {10.1099/jmm.0.001878}
}
EUVIMED